BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim JY, Kronbichler A, Eisenhut M, Hong SH, van der Vliet HJ, Kang J, Shin JI, Gamerith G. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1798. [PMID: 31731749 DOI: 10.3390/cancers11111798] [Cited by in Crossref: 59] [Cited by in F6Publishing: 68] [Article Influence: 14.8] [Reference Citation Analysis]
Number Citing Articles
1 Ellingsen EB, Bjørheim J, Gaudernack G. Therapeutic cancer vaccination against telomerase: clinical developments in melanoma. Curr Opin Oncol 2023;35:100-6. [PMID: 36700456 DOI: 10.1097/CCO.0000000000000922] [Reference Citation Analysis]
2 Fitzsimmons T, Singh N, Walker T, Newton C, Evans D, Crosbie E, Ryan N. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.. [DOI: 10.21203/rs.3.rs-2493110/v1] [Reference Citation Analysis]
3 Qi R, Yu Y, Shen M, Lv D, He S. Current status and challenges of immunotherapy in ALK rearranged NSCLC. Front Oncol 2022;12:1016869. [PMID: 36591504 DOI: 10.3389/fonc.2022.1016869] [Reference Citation Analysis]
4 Geng N, Hu T, He C. Identification of DDX60 as a Regulator of MHC-I Class Molecules in Colorectal Cancer. Biomedicines 2022;10. [PMID: 36551849 DOI: 10.3390/biomedicines10123092] [Reference Citation Analysis]
5 Sandhu S, Atkinson V, Cao MG, Medina T, Rivas AS, Menzies AM, Caro I, Roberts L, Song Y, Yan Y, Guo Y, Xue C, Long GV. Phase 1b Study of Cobimetinib Plus Atezolizumab in Patients with Advanced BRAFV600 Wild-Type Melanoma Progressing on Prior Anti–Programmed Death-1 Therapy. European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.10.019] [Reference Citation Analysis]
6 Diep YN, Kim TJ, Cho H, Lee LP. Nanomedicine for advanced cancer immunotherapy. Journal of Controlled Release 2022;351:1017-1037. [DOI: 10.1016/j.jconrel.2022.10.004] [Reference Citation Analysis]
7 Varma R, Wright M, Abraham J, Kruse M. Immune checkpoint inhibition in early-stage triple-negative breast cancer. Expert Rev Anticancer Ther 2022;22:1225-38. [PMID: 36278877 DOI: 10.1080/14737140.2022.2139240] [Reference Citation Analysis]
8 Anderson TS, Wooster AL, Piersall SL, Okpalanwaka IF, Lowe DB. Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Semin Cancer Biol 2022;86:981-96. [PMID: 35149179 DOI: 10.1016/j.semcancer.2022.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Wang X, Liu X, Hugo W, Si L, Shi H. Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1065937] [Reference Citation Analysis]
10 Abbasian MH, Ardekani AM, Sobhani N, Roudi R. The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment. Cancers 2022;14:5144. [DOI: 10.3390/cancers14205144] [Reference Citation Analysis]
11 Zhao D, Wang L, Chen Z, Zhang L, Xu L. KRAS is a prognostic biomarker associated with diagnosis and treatment in multiple cancers. Front Genet 2022;13:1024920. [DOI: 10.3389/fgene.2022.1024920] [Reference Citation Analysis]
12 Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P, Vuagnat P, Besse B, Planchard D, Hollebecque A, Champiat S, Marabelle A, Michot J, Massard C, Mezquita L. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. Cancers 2022;14:5078. [DOI: 10.3390/cancers14205078] [Reference Citation Analysis]
13 Kudo-saito C, Boku N, Hirano H, Shoji H. Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer. Front Immunol 2022;13:1009701. [DOI: 10.3389/fimmu.2022.1009701] [Reference Citation Analysis]
14 Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G. Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03624-z] [Reference Citation Analysis]
15 Xiang X, Li Y, Yang X, Guo W, Zhou P. Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis. BMJ Open 2022;12:e058692. [PMID: 35926995 DOI: 10.1136/bmjopen-2021-058692] [Reference Citation Analysis]
16 Damato A, Rotolo M, Caputo F, Borghi E, Iachetta F, Pinto C. New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. Life (Basel) 2022;12:1137. [PMID: 36013315 DOI: 10.3390/life12081137] [Reference Citation Analysis]
17 Pfitzer L, Lybaert L, Bogaert C, Fant B. Improving T-cell mediated immunogenic epitope identification via machine learning: the neoIM model.. [DOI: 10.1101/2022.06.03.494687] [Reference Citation Analysis]
18 Lau TTY, Sefid Dashti ZJ, Titmuss E, Pender A, Topham JT, Bridgers J, Loree JM, Feng X, Pleasance ED, Renouf DJ, Schrader KA, Sun S, Ho C, Marra MA, Laskin J, Karsan A. The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space. J Mol Diagn 2022;24:609-18. [PMID: 35367630 DOI: 10.1016/j.jmoldx.2022.02.004] [Reference Citation Analysis]
19 Caksa S, Baqai U, Aplin AE. The future of targeted kinase inhibitors in melanoma. Pharmacol Ther 2022;239:108200. [PMID: 35513054 DOI: 10.1016/j.pharmthera.2022.108200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Meng G, Liu X, Ma T, Lv D, Sun G. Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis. PLoS One 2022;17:e0263629. [PMID: 35113949 DOI: 10.1371/journal.pone.0263629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Morrison J, Balega J, Buckley L, Clamp A, Crosbie E, Drew Y, Durrant L, Forrest J, Fotopoulou C, Gajjar K, Ganesan R, Gupta J, Hughes J, Miles T, Moss E, Nanthakumar M, Newton C, Ryan N, Walther A, Taylor A. British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology 2022;270:50-89. [DOI: 10.1016/j.ejogrb.2021.11.423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
22 Cristescu R, Aurora-Garg D, Albright A, Xu L, Liu XQ, Loboda A, Lang L, Jin F, Rubin EH, Snyder A, Lunceford J. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer 2022;10:e003091. [PMID: 35101941 DOI: 10.1136/jitc-2021-003091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
23 Kumar A, Weller KP, Vilgelm AE. Personalized cancer immunotherapy. Engineering Technologies and Clinical Translation 2022. [DOI: 10.1016/b978-0-323-90949-5.00012-7] [Reference Citation Analysis]
24 Seegobin K, Majeed U, Wiest N, Manochakian R, Lou Y, Zhao Y. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. Front Oncol 2021;11:750657. [PMID: 34926258 DOI: 10.3389/fonc.2021.750657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhao J, Dong Y, Bai H, Duan J, Wang G, Xu J, Wang J, Wang Z. Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis. Journal of the National Cancer Center 2021. [DOI: 10.1016/j.jncc.2021.11.006] [Reference Citation Analysis]
26 Plummer R, Dean E, Arkenau HT, Redfern C, Spira AI, Melear JM, Chung KY, Ferrer-Playan J, Goddemeier T, Locatelli G, Dong J, Fleuranceau-Morel P, Diaz-Padilla I, Shapiro GI. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer 2021;163:19-26. [PMID: 34894455 DOI: 10.1016/j.lungcan.2021.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ledys F, Kalfeist L, Galland L, Limagne E, Ladoire S. Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. Cancers (Basel) 2021;13:5999. [PMID: 34885109 DOI: 10.3390/cancers13235999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Lee D, Kim NW, Kim JY, Lee JH, Noh JH, Lee H, Jeong JW, Lee S, Kang J. Sarcopenia's Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:5329. [PMID: 34830611 DOI: 10.3390/jcm10225329] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Li Y, Luo Y. Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation. Sci Rep 2021;11:21072. [PMID: 34702927 DOI: 10.1038/s41598-021-00626-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Li Y, Ma Y, Wu Z, Zeng F, Song B, Zhang Y, Li J, Lui S, Wu M. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:751407. [PMID: 34659255 DOI: 10.3389/fimmu.2021.751407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
31 Sun Y, Yang Q, Shen J, Wei T, Shen W, Zhang N, Luo P, Zhang J. The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Front Cell Dev Biol 2021;9:745859. [PMID: 34660603 DOI: 10.3389/fcell.2021.745859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Montalban-Arques A, Katkeviciute E, Busenhart P, Bircher A, Wirbel J, Zeller G, Morsy Y, Borsig L, Glaus Garzon JF, Müller A, Arnold IC, Artola-Boran M, Krauthammer M, Sintsova A, Zamboni N, Leventhal GE, Berchtold L, de Wouters T, Rogler G, Baebler K, Schwarzfischer M, Hering L, Olivares-Rivas I, Atrott K, Gottier C, Lang S, Boyman O, Fritsch R, Manz MG, Spalinger MR, Scharl M. Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe 2021;29:1573-1588.e7. [PMID: 34453895 DOI: 10.1016/j.chom.2021.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
33 Wang M, Zhu J, Zhao F, Xiao J. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Antitumor Immunosuppression of EGFR Wild Type Lung Cancers With Low PD-L1 Expression. Front Oncol 2021;11:643503. [PMID: 34595103 DOI: 10.3389/fonc.2021.643503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Watson RA, Tong O, Cooper R, Taylor CA, Sharma PK, de Los Aires AV, Mahé EA, Ruffieux H, Nassiri I, Middleton MR, Fairfax BP. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity. Sci Immunol 2021;6:eabj8825. [PMID: 34597125 DOI: 10.1126/sciimmunol.abj8825] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
35 Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. [PMID: 34518290 DOI: 10.1136/jitc-2021-002794] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
36 Martínez-Cortés F, Servín-Blanco R, Domínguez-Romero AN, Munguía ME, Guzman Valle J, Odales J, Gevorkian G, Manoutcharian K. Generation of cancer vaccine immunogens derived from Oncofetal antigen (OFA/iLRP) using variable epitope libraries tested in an aggressive breast cancer model. Mol Immunol 2021;139:65-75. [PMID: 34454186 DOI: 10.1016/j.molimm.2021.08.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Huang T, Chen X, Zhang H, Liang Y, Li L, Wei H, Sun W, Wang Y. Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:706652. [PMID: 34395281 DOI: 10.3389/fonc.2021.706652] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
38 Ellingsen EB, Mangsbo SM, Hovig E, Gaudernack G. Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. Front Immunol 2021;12:682492. [PMID: 34290704 DOI: 10.3389/fimmu.2021.682492] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
39 Ferreira JA, Relvas-Santos M, Peixoto A, M N Silva A, Lara Santos L. Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines. Genomics Proteomics Bioinformatics 2021:S1672-0229(21)00097-8. [PMID: 34118464 DOI: 10.1016/j.gpb.2021.03.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
40 Kumar A, Watkins R, Vilgelm AE. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. Front Immunol 2021;12:690499. [PMID: 34140957 DOI: 10.3389/fimmu.2021.690499] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
41 Fenizia F, Alborelli I, Costa JL, Vollbrecht C, Bellosillo B, Dinjens W, Endris V, Heydt C, Leonards K, Merkelback-Bruse S, Pfarr N, van Marion R, Allen C, Chaudhary R, Gottimukkala R, Hyland F, Wong-Ho E, Jermann P, Machado JC, Hummel M, Stenzinger A, Normanno N. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium. J Mol Diagn 2021;23:882-93. [PMID: 33964449 DOI: 10.1016/j.jmoldx.2021.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Galvano A, Gristina V, Malapelle U, Pisapia P, Pepe F, Barraco N, Castiglia M, Perez A, Rolfo C, Troncone G, Russo A, Bazan V. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. ESMO Open 2021;6:100124. [PMID: 33940346 DOI: 10.1016/j.esmoop.2021.100124] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
43 De Wispelaere W, Annibali D, Tuyaerts S, Lambrechts D, Amant F. Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types? Cancers (Basel) 2021;13:2040. [PMID: 33922556 DOI: 10.3390/cancers13092040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Apollonio B, Ioannou N, Papazoglou D, Ramsay AG. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Front Oncol 2021;11:626818. [PMID: 33842331 DOI: 10.3389/fonc.2021.626818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
45 Nan Z, Guoqing W, Xiaoxu Y, Yin M, Xin H, Xue L, Rong W. The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Biomed Res Int 2021;2021:1780860. [PMID: 33791360 DOI: 10.1155/2021/1780860] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
46 Salem D, Chelvanambi M, Storkus WJ, Fecek RJ. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation. Front Immunol 2021;12:629519. [PMID: 33746966 DOI: 10.3389/fimmu.2021.629519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
47 Kim A, Lim SM, Kim JH, Seo JS. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma. Front Immunol 2021;12:598671. [PMID: 33717076 DOI: 10.3389/fimmu.2021.598671] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
48 Kerr KM, Bibeau F, Thunnissen E, Botling J, Ryška A, Wolf J, Öhrling K, Burdon P, Malapelle U, Büttner R. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer 2021;154:161-75. [PMID: 33690091 DOI: 10.1016/j.lungcan.2021.02.026] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 23.5] [Reference Citation Analysis]
49 Cobo M, Rodríguez-Abreu D, Pérez Parente D, Ruiz Gracia P, González JG. Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review. Oncol Ther 2021;9:41-53. [PMID: 33582978 DOI: 10.1007/s40487-021-00139-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, Deguchi T, Kato Y, Yamamoto S, Yamamoto K, Toda M, Nakajima C, Suzuki Y, Murata S, Ohashi K. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol 2021;5:10. [PMID: 33580183 DOI: 10.1038/s41698-021-00147-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
51 Haist M, Stege H, Grabbe S, Bros M. The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. Cancers (Basel) 2021;13:E210. [PMID: 33430105 DOI: 10.3390/cancers13020210] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 17.5] [Reference Citation Analysis]
52 Tay C, Qian Y, Sakaguchi S. Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy. Cancers (Basel) 2020;13:E48. [PMID: 33375291 DOI: 10.3390/cancers13010048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Tay C, Qian Y, Sakaguchi S. Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy. Cancers (Basel) 2020;13:E48. [PMID: 33375291 DOI: 10.3390/cancers13010048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
54 Huo J, Wu L, Zang Y. A Prognostic Model of 15 Immune-Related Gene Pairs Associated With Tumor Mutation Burden for Hepatocellular Carcinoma. Front Mol Biosci 2020;7:581354. [PMID: 33282911 DOI: 10.3389/fmolb.2020.581354] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
55 Sardana R, Mishra SK, Williamson SR, Mohanty A, Mohanty SK. Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies. Semin Oncol 2020;47:367-79. [PMID: 33160642 DOI: 10.1053/j.seminoncol.2020.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
56 Buonaguro L, Tagliamonte M. Selecting Target Antigens for Cancer Vaccine Development. Vaccines (Basel) 2020;8:E615. [PMID: 33080888 DOI: 10.3390/vaccines8040615] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
57 Yang Z, Wei S, Deng Y, Wang Z, Liu L. Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis. Jpn J Clin Oncol 2020;50:1023-31. [PMID: 32542383 DOI: 10.1093/jjco/hyaa076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
58 Macek Jilkova Z, Aspord C, Decaens T. Reply to Comment on "Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" Cancers 2019, 11, 1554. Cancers (Basel) 2020;12:E2673. [PMID: 32962118 DOI: 10.3390/cancers12092673] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
59 Sorigue M, Cañamero E, Sancho JM. Precision medicine in follicular lymphoma: Focus on predictive biomarkers. Hematol Oncol 2020;38:625-39. [PMID: 32700331 DOI: 10.1002/hon.2781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Marmorino F, Boccaccino A, Germani MM, Falcone A, Cremolini C. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. Cancers (Basel). 2020;12. [PMID: 32824490 DOI: 10.3390/cancers12082317] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
61 Osipov A, Lim SJ, Popovic A, Azad NS, Laheru DA, Zheng L, Jaffee EM, Wang H, Yarchoan M. Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. Clin Cancer Res 2020;26:4842-51. [PMID: 32586938 DOI: 10.1158/1078-0432.CCR-20-0458] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 13.7] [Reference Citation Analysis]
62 Bolis M, Paroni G, Fratelli M, Vallerga A, Guarrera L, Zanetti A, Kurosaki M, Garattini SK, Gianni' M, Lupi M, Pattini L, Barzago MM, Terao M, Garattini E. All-Trans Retinoic Acid Stimulates Viral Mimicry, Interferon Responses and Antigen Presentation in Breast-Cancer Cells. Cancers (Basel) 2020;12:E1169. [PMID: 32384653 DOI: 10.3390/cancers12051169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
63 Zhang F, Gong W. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis. Int Immunopharmacol 2020;83:106481. [PMID: 32339986 DOI: 10.1016/j.intimp.2020.106481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
64 van Elsas MJ, van Hall T, van der Burg SH. Future Challenges in Cancer Resistance to Immunotherapy. Cancers (Basel) 2020;12:E935. [PMID: 32290124 DOI: 10.3390/cancers12040935] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
65 El Bairi K, Afqir S. Next-Generation Sequencing for Colorectal Cancer Management. Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing 2020. [DOI: 10.1007/978-3-030-53821-7_4] [Reference Citation Analysis]
66 Zhao J, Dong Y, Ba H, Duan J, Wang G, Xu J, Wang Z, Wang J. The Effect of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Comprehensive Meta-Analysis. SSRN Journal. [DOI: 10.2139/ssrn.3738656] [Reference Citation Analysis]